Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

A compound having the structural formula (Ia):

• optionally in the form of a pharmaceutically acceptable salt, N-oxide, a solvate or hydrate thereof, wherein
• L1 is —S— or a bond;
• R1 is selected from the group consisting of C1-C8 alkyl, C1-C8 alkenyl and C1-C8 alkynyl, each unsubstituted or fluorinated,
• L2 is a bond or —CH2—;
• Q is —C(O)OH, —C(O)OR2A, or —C(O)NR2BR2A, in which
• each R2A is independently selected from H and C1-C3 alkyl, and
• each R2B is independently selected from H and C1-C3 alkyl;
• L3 is a bond;
• R3 is phenyl or monocyclic heteroaryl, optionally substituted with 1-5 R3E, in which
• each R3E is independently selected from oxo, optionally-substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, —CN, SF5, —N3, —C(O)R3F, —SR3F, —S(O)1-2R3F, —OR3F, —NR3GR3F, —C(O)R3F, —C(O)NR3GR3F, —NR3GC(O)R3F, —C(S)NR3GR3F, —NR3GC(S)R3F, —C(O)OR3F, —OC(O)R3F, —C(O)SR3F, —SC(O)R3F, —C(S)OR3F, —OC(S)R3F, —C(S)SR3F, —SC(S)R3F, —S(O)1-2OR3F, —OS(O)1-2R3F, —S(O)1-2NR3GR3F, and —NR3GS(O)1-2R3F;
• each R3F is independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl and
• each R3G is independently selected from H, C1-C3 alkyl, and C1-C3 fluoroalkyl;
• L4 is a bond,
• R4 is selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally-substituted C1-C8 alkenyl and optionally substituted C1-C8 alkynyl;
• L5 is a bond,
• R5 is cycloalkyl or heterocycloalkyl, each optionally substituted with 1-5 R5E, in which
• each R5E is independently selected from oxo, optionally-substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, —CN, —SF5, —N3, —C(O)R5F, SR5F, —S(O)12R5F, —OR5F, —NRSGR5F, —C(O)R5F, —C(O)NR5GR5F, —NR5GC(O)R5F, —C(S)NR5GR5F, —NR1GC(S)R5F, —C(O)OR5F, —OC(O)R5F, —C(O)SR5F, —SC(O)R5F, —C(S)OR5F, —OC(S)R5F, —C(S)SR5F, —SC(S)R5F, —S(O)1-2OR5F, —OS(O)1-2R5F, —S(O)1-2NR5GR5F and —NR5GS(O)1-2R5F;
• each R5F is independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl and
• each R5G is independently selected from H and C1-C3 alkyl;
• wherein
• each optionally substituted alkyl, alkenyl and alkynyl is unsubstituted, fluorinated or substituted with one or two hydroxyl groups;
• each cycloalkyl has 3-10 ring carbons and is saturated or partially unsaturated, and optionally has one or two fused cycloalkyl rings, each fused ring having 3-8 ring members;
• each heterocylcloalkyl has 3-10 ring members and 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and is saturated or partially unsaturated, and optionally has one or two fused cycloalkyl rings, each having 3-8 ring members;
• each monocyclic heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.